Re-expression of p16 gene in the myeloma cell line U266 induced by synergy of sodium butyrate and 5-Aza-2'-deoxycytidine. 2002

Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
Department of Hematology, First Hospital of Peking University, Beijing 100034, China. duhongling@yahoo.com

OBJECTIVE To understand the synergic effect of histone deacetylase inhibitor sodium butyrate (SB) and demethylating agent 5-Aza-2'- deoxycytidine (5-Aza-CdR) on cell growth and to explore the possibility of re-expression of the hypermethylated and silenced p16 gene in the myeloma cell line U266. METHODS U266 cells were cultured in RPMI 1640 in the presence of varied doses of SB and 5-Aza-CdR, and the growth curve was obtained by trypan-blue exclusion assay and cell count. The cell cycle was analyzed by flow cytometry and the expression level of mRNA and protein of p16 gene were detected by reverse transcriptase-PCR and Western blotting, respectively. RESULTS The cell growth was arrested by treatment with 5-Aza-CdR alone or SB alone. Increased inhibition effect was shown in synergic treatment of SB and 5-Aza-CdR. The G(1) phase of cell cycle was arrested by 5-Aza-CdR combined with SB, which, however, did not occur when SB or 5-Aza-CdR was used alone. 5-Aza-CdR alone induced the expression of p16 gene in a concentration-dependent manner, whereas SB alone only induced its low-level expression. The expression level of both mRNA and protein of p16 gene was increased significantly by synergic application of SB and 5-Aza-CdR. CONCLUSIONS Hypermethylated and silenced p16 gene in U266 cell line can be markedly reactivated by synergic treatment with demethylating agent 5-Aza-CdR and histone deacetylase inhibitor SB, and the cell growth can be inhibited and cell cycle arrested at G(1) phase.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D002087 Butyrates Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. Butyrate,n-Butyrate,Butanoic Acids,Butyric Acids,Acids, Butanoic,Acids, Butyric,n Butyrate
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077209 Decitabine An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA. 2'-Deoxy-5-azacytidine,5-Aza-2'-deoxycytidine,5-AzadC,5-Azadeoxycytidine,5-Deoxyazacytidine,5AzadC,AzadC Compound,Dacogen,Decitabine Mesylate,NSC 127716,NSC-127716,2' Deoxy 5 azacytidine,5 Aza 2' deoxycytidine,5 Azadeoxycytidine,5 Deoxyazacytidine,Compound, AzadC,Mesylate, Decitabine,NSC127716
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D001374 Azacitidine A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent. Azacytidine,5-Azacytidine,NSC-102816,Vidaza,5 Azacytidine,NSC 102816,NSC102816
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
June 2004, Ai zheng = Aizheng = Chinese journal of cancer,
Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
October 2002, Ai zheng = Aizheng = Chinese journal of cancer,
Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
February 2001, World journal of gastroenterology,
Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
September 2012, World journal of surgical oncology,
Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
October 2016, Oncology reports,
Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
December 2003, Zhonghua yi xue za zhi,
Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
March 2018, Pediatric research,
Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
February 2007, Zhongguo shi yan xue ye xue za zhi,
Hong-Ling Du, and Li-Min Ren, and Hua Chen, and Yan Zhu, and Yu Qi
November 2023, International journal of molecular sciences,
Copied contents to your clipboard!